Amelorative and Hepatoprotective Effects of Fisetin on Acute Murine Toxoplasmosis

Elmehy, Dalia A.; SALAMA, AMINA; Soliman, Nema A.; Elkholy, Reem; Tahoon, Dina; Mady, Rasha Fadly; Gamea, Ghada A.

doi:10.21608/jesp.2021.165943

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, the highest SR and the longest ST were reported in SMZ-TMP, and probiotic combined-treated group (95% and 16 days, respectively). Consistent with the current results, Elmehy et al (2021) reported enhanced SR of mice treated with immunomodulatory adjuvant therapy. Contrarily, there was a difference in ST and SR on comparing these results with other experimental studies.…”

Section: Discussionsupporting

confidence: 92%

“…Furthermore, they were not effective against the tissue cysts (Alday and Doggett 2017). Later, sulfadiazine was replaced with clindamycin, which was less effective in preventing relapse and had similar toxicity rates (Elmehy et al 2021). Other treatment options include atovaquone or azithromycin, which have been studied to be used as an alternate therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice

et al. 2023

View full text Add to dashboard Cite

Toxoplasmosis is an immunologically complex disease, particularly in immunocompromised patients. Although there are several therapeutic regimens for such disease, the majority of them have many drawbacks. Therefore, it is of utmost importance to improve the current regimen in an effort to achieve a well-tolerated therapy while also enhancing the host immune response. Famous for their immunomodulatory effect, Lactobacillus delbrueckii and Lactobacillus fermentum probiotics were chosen to be evaluated in this study as an adjuvant therapy against the virulent RH Toxoplasma gondii (T. gondii) strain. Experimental mice were divided into control and treated groups. The control group was further subdivided into two groups: group I: 10 uninfected mice and group II: 20 infected untreated mice. The treated experimental group was subdivided into three groups (20 mice each); group III: sulfamethoxazole-trimethoprim (SMZ-TMP) treated, group IV: probiotics treated, and group V: SMZ-TMP combined with probiotics. The results obtained revealed that combined therapy increased survival rate and time up to 95% and 16 days, respectively, with an 82% reduction of tachyzoites and marked distortion, as detected by the scanning electron microscope (SEM). Additionally, combined therapy alleviated the severity and the extent of the inflammatory cells’ infiltration, thereby reducing hepatocyte degeneration. Intriguingly, serum IF-γ level showed a significant increase to 155.92 ± 10.12 ng/L with combined therapy, reflecting the immunological role of the combined therapy. The current results revealed that probiotics have a high adjuvant potential in alleviating the impact of toxoplasmosis. Using probiotics as a synergistic treatment to modulate conventional therapy in systemic toxoplasmosis may gain popularity due to their low cost and current availability.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…8 F). The results indicated that although the IL-10 level was decreased in chondrocytes stimulated with IL-1β compared with the untreated group (control group), the treatment with FNPs, like fisetin 48 , 49 , increased its level in IL-1β pretreated human chondrocytes. In general, these results showed that FNPs can inhibit the inflammatory responses induced by IL-1β, including the expression of TNF-α, and IL-6, and reduce the degradation of Sox-9, COL2, and SirT1 in OA chondrocyte cells.…”

Section: Resultsmentioning

confidence: 90%

“…However, similar to fisetin, FNPs reduced TNF-α and IL-6 mRNA expression in IL-1β stimulated cells. Next, the effect of FNPs on the mRNA expression of IL-10, a well-known anti-inflammatory cytokine 48 , 49 , was investigated in IL-1β stimulated human chondrocytes (Fig. 8 F).…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis

Nabizadeh,

Nasrollahzadeh,

Shabani

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Cartilage lesions, especially osteoarthritis (OA), are a common health problem, causing pain and disability in various age groups, principally in older adults and athletes. One of the main challenges to be considered in cartilage tissue repair is the regeneration of cartilage tissue in an active inflammatory environment. Fisetin has various biological effects including anti-inflammatory, antioxidant, apoptotic, and antiproliferative activities. The only disadvantages of fisetin in the pharmaceutical field are its instability and low solubility in aqueous media. This study is aimed at preparing chitosan (CS)-based nanoparticles to yield fisetin with improved bioavailability features. Then, the effect of fisetin-loaded nanoparticles (FNPs) on inflammatory responses in interleukin-1β (IL-1β) pretreated human chondrocytes has also been investigated. FNPs presented an average size of 363.1 ± 17.2 nm and a zeta potential of + 17.7 ± 0.1 mV with encapsulation efficiency (EE) and loading capacity (LC) of 78.79 ± 7.7% and 37.46 ± 6.6%, respectively. The viability of human chondrocytes was not affected by blank nanoparticles (BNPs) up to a concentration of 2000 μg/mL. In addition, the hemolysis results clearly showed that FNPs did not damage the red blood cells (RBCs) and had good hemocompatibility within the range investigated. FNPs, similar to fisetin, were able to inhibit the inflammatory responses induced by IL-1β such as the expression of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) while increasing the production of an anti-inflammatory cytokine such as interleukin-10 (IL-10). Overall, the in vitro evaluation results of the anti-inflammatory activity showed that FNPs can serve as delivery systems to transfer fisetin to treat inflammation in OA.

show abstract

The possible ameliorating role of fisetin on hepatic changes induced by fluoxetine in adult male albino rats: Histological, immunohistochemical, and biochemical study

Halim¹,

Shaer²

2023

J Microsc Ultrastruct

View full text Add to dashboard Cite

Amelorative and Hepatoprotective Effects of Fisetin on Acute Murine Toxoplasmosis

Cited by 3 publications

References 39 publications

The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice

The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice

Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis

The possible ameliorating role of fisetin on hepatic changes induced by fluoxetine in adult male albino rats: Histological, immunohistochemical, and biochemical study

Contact Info

Product

Resources

About